One (1%) unemployed patient was part-time student. Five (5%) patients were employed at both contact 1 and contact 2. Figure 1 shows employment status at contact 1 and contact 2. Figure 1 Employment status of patients with chronic fatigue syndrome at first contact (contact 1) and follow-up (contact 2). Logistic regression analyses showed Idelalisib clinical that being employed at contact 2 was associated with lack of arthralgia (OR=0.3, p=0.028) and reporting improvement (OR=1.8, p=0.062) at contact 1. Another logistic regression analyses showed that being employed

at contact 2 was associated with low FSS score at contact 2 (OR=0.53, p<0.001), lack of arthralgia (OR=0.40,

p=0.041) and lack of concentration problems (OR=0.32, p=0.064), but none of the other symptoms reported at contact 2. Secondary measures There was no correlation between FSS score at contact 2 and degree of PEM at contact 1 (p=0.57). There was no correlation between mode of onset of fatigue after mononucleosis (acute or taking months) and FSS score at contact 2 (p=0.61). Neither was there any correlation between employment status at contact 2 and degree of PEM at contact 1 (p=0.91) nor mode of onset (P=0.59). There was no correlation between degree of PEM at contact 1 and FSS score at contact 1 (p=0.99). Based on FSS change from contact 1 to contact 2, 38 (44%; FSS improvement>1) improved, 42 (48%; FSS change ≤1 and ≥−1) did not change and 7 (8%) worsened (FSS change <−1). Based on self-assessment 10 (12%) had worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had recovered at contact 2. The correlation between self-rated clinical change between contact 1 and contact 2 and employment status at

contact 2 was r=0.54 (p<0.001). The correlation between change in FSS from contact 1 to contact 2 and employment status was r=0.30 (p=0.01). The correlation between FSS score at contact 2 and employment was r=0.51 (p<0.001). The correlation between WSAS score and employment was r=0.74 (p<0.001). The correlation between WSAS score and FSS score at contact 2 was r=0.81 (p<0.001). Clinical characteristics based on evaluation Cilengitide at contact 1 and contact 2 are shown in table 1. Mean FSS score dropped from 6.4 to 5.0 (p<0.001). CFS symptom pattern showed significant less frequencies of concentration and memory problems, headache, myalgia, sleep disturbances at contact 2 compared to contact 1 (all p<0.005), but no changes as to depression and arthralgia. A comparison between patients with FSS ≥5 versus FSS<5 at contact 2 is shown in tables 2 and ​and33.